// App-Quantinova.ai

3375 : Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Researchers

Presenter

  • Annie Borel-Derlon

Principal Investigators

  • Jenny Goudemand

  • Wil Stevens

  • Francoise Bridey

  • Celine Henriet

  • Segolene Claeyssens

  • Pierre-Marie Sie

  • Philippe Moreau

  • Marie-Anne Bertrand

  • Chantal Rothschild

  • Benoit Guillet

  • Jeanne Yvonne Borg

  • Catherine Chatelanaz

Medical Centers

  • Hemophilia Center, Pontchaillou University Hospital, Rennes, France,

  • CHU Besancon, Besancon, France

  • Hemophilia treatment center, Hopital Purpan, Toulouse, France

  • Laboratoire -Hematologie, Hopital Antoine Beclere, Clamart, France

  • Hemophilia treatment center, Hopital Necker, Paris, France

  • Hemophilia treatment center, Hopital Charles Nicolle, Rouen, France

  • Hemophilia treatment center, Pavillon Reuilly, Le Mans, France

  • CHU de Caen, Laboratoire dhematologie, Caen, France

  • Hopital Cardiologique, Centre regional de traitement de -hemophilie, Lille, France

Locations

  • France

Companies

  • LFB Biomedicaments

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Venous thrombosis

  • Hematoma

Biomarkers

  • von Willebrand factor

Drug/Treatment

  • FVIII

  • Hemostatic Solution

  • Wilfactin

Outcome

  • N/A

Study Design

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved